Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAF(V600E) mutation

In vitro, EGFR inhibition, combined with the BRAF inhibitor vemurafenib, causes synergistic cytotoxicity for BRAF(V600E) metastatic colorectal cancer (mCRC), further augmented by irinotecan. The safety and efficacy of vemurafenib, irinotecan, and cetuximab in BRAF-mutated malignancies are not define...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer Discov
Hoofdauteurs: Hong, David S., Morris, Van K., Osta, Badi El, Sorokin, Alexey V., Janku, Filip, Fu, Siqing, Overman, Michael J., Piha-Paul, Sarina, Subbiah, Vivek, Kee, Bryan, Tsimberidou, Apostolia, Fogelman, David, Bellido, Jorge, Shureiqi, Imad, Huang, Helen, Atkins, Johnique, Tarcic, Gabi, Sommer, Nicolas, Lanman, Richard, Meric-Bernstam, Funda, Kopetz, Scott
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2016
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5562357/
https://ncbi.nlm.nih.gov/pubmed/27729313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0050
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items